The limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging

by Fortes Francisco A, Lewis MD, Jayawardhana S, Taylor MC, Chatelain E, Kelly JM. Antimicrobial Agents and Chemotherapy 2015 May 26. pii: AAC.00520-15.

Summary: The anti-fungal drug posaconazole has shown significant activity against Trypanosoma cruzi in vitro and in vivo, but despite this displayed limited curative potential. Drug testing is problematic in experimental Chagas disease because of difficulties in demonstrating sterile cure, particularly during the chronic stage of infection when parasite burden is extremely low and tissue distribution ill-defined. As an in vivo screening model for Chagas, this highly sensitive bioluminescence imaging system is predictive, reproducible and adaptable to diverse treatment schedules. It should provide greater assurance that drugs are not advanced prematurely into clinical trial.

Click here to read the article / PDF

 

 

 


Letter to the Editor
Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drug
Urbina JA and McKerrow JH
Antimicrob. Agents Chemother. December 2015 ; 59:12 7923-7924 doi:10.1128/AAC.01714-15
Click here to access the letter

Author Reply
Reply to “Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs
Fortes Francisco A, Lewis MD, Jayawardhana S, Taylor MC, Chatelain E, and Kelly JM
Antimicrob. Agents Chemother. December 2015 ; 59:12 7925 doi:10.1128/AAC.02022-15
Click here to access the reply